Lysophosphatidic acid (LPA)-antibody (504B3) engagement detected by interferometry identifies off-target binding.
Manisha RayYasuyuki KiharaDarryl J BornhopJerold ChunPublished in: Lipids in health and disease (2021)
Antibody binding specificity and sensitivity, particularly involving lipid ligands, can be assessed in solution and without labels using FSA-CIR. These findings could affect interpretations of both current and past basic and clinical studies employing 504B3 and related anti-LPA antibodies.